7 Ago (Reuters) – Hikma Pharmaceuticals has begun producing remdesivir, a remedy approved for COVID-19 by US company Gilead, for an unwrified amount at its plant in Portugal, said the leading executive of the British company.
The corporation will supply the first batches of the antiviral drug “soon” and Gilead is expected to distribute the treatment, which will be the first to light up through the disease caused by the new coronavirus.
“The terms of the agreement are confidential, we are only a contract manufacturer for Gilead; they order the products as they expect the sales to be,” Chief Executive Siggi Olafsson told Reuters on Friday.
All quotes were delayed for at least 15 minutes. See here for a complete list of transactions and delays.
© 2020 Reuters. All rights are reserved.